Journal Mobile Options
Table of Contents
Vol. 133, No. 4, 2004
Issue release date: April 2004
Int Arch Allergy Immunol 2004;133:317–329
(DOI:10.1159/000077351)

The Basophil-Specific Ectoenzyme E-NPP3 (CD203c) as a Marker for Cell Activation and Allergy Diagnosis

Bühring H.-J. · Streble A. · Valent P.
aDepartment of Internal Medicine II, Division of Hematology, Immunology and Oncology, University of Tübingen, Tübingen, Germany; bDepartment of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Vienna, Austria

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Basophils are effector cells of allergic reactions. These cells produce and store a number of vasoactive and immunomodulatory mediators. During an allergic reaction, basophils can release their mediator substances into the extracellular space and thus contribute to the clinical picture and symptoms in allergy. The phenotypic hallmark of basophils is expression of high-affinity IgE receptors (FcεRI) on their cell surface together with expression of the activation-linked molecule CD203c. This ectoenzyme is located both on the plasma membrane and in the cytoplasmic compartment of basophils. Cross-linking of the FcεRI by an allergen or anti-IgE antibody results in a rapid upregulation of intracellular CD203c molecules to the cell surface and is accompanied by mediator release. CD203c is therefore a promising target molecule for a flow cytometry-based test to analyze sensitized individuals and patients with type I allergy. In the present article, we review the current knowledge of CD203c with special regard to its tissue distribution and regulation in basophil activation. In addition, we discuss the application of CD203c in allergy diagnosis.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Narita M, Goji J, Nakamura H, Sano K: Molecular cloning, expression, and localization of a brain-specific phosphodiesterase I/nucleotide pyrophosphatase (PD-Iα) from rat brain. J Biol Chem 1994;269:28235–28242.
  2. Goding JW: Ecto-enzymes: Physiology meets pathology. J Leukoc Biol 2000;67:285–311.
  3. Buckley MF, Loveland KA, McKinstry WJ, Garson OM, Goding JW: Plasma cell membrane glycoprotein PC-1:cDNA cloning of the human molecule, amino acid sequence, and chromosomal location. J Biol Chem 1990;265:17506–17511.
  4. Murata J, Lee HY, Clair T, Krutzsch HC, Arestad AA, Sobel ME, Liotta LA, Stracke ML: cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases. J Biol Chem 1994;269:30479–30484.
  5. Deissler H, Lottspeich F, Rajewski MF: Affinity purification and cDNA cloning of rat neural differentiation and tumor cell surface antigen gp130RB13-6 reveals relationship to human and murine PC-1. J Biol Chem 1995;270:9849–9855.
  6. Deissler H, Blass-Kampmann S, Bruyneel E, Mareel M, Rajewski MF: Neural cell surface differentiation antigen gp130 (RB13-6) induces fibroblasts and glioma cells to express astroglial proteins and invasive properties. FASEB J 1999;13:657–666.
  7. Okawa A, Nakamura I, Goto S, Moriya H, Nakamura Y, Ikegawa S: Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 1998;19:271–273.
  8. Zimmermann H, Beaudoin AR, Bollen M, et al: Proposed nomenclature for two novel nucleotide hydrolysing enzyme families expressed on the cell surface; in Vanduffel L, Lemmens R (eds): Ecto-ATPases and Related Ectonucleotidases. Maastricht, Shaker, 2000, pp 1–8.
  9. Zimmermann H: Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 2000;362:299–309.
  10. Vollmayer P, Clair T, Goding JW, Sano K, Servos J, Zimmermann H: Hydrolysis of diadenosine polyphosphates by nucleotide pyrophosphatases/phosphodiesterases. Eur J Biochem 2003;270:2971–2978.
  11. Goding JW, Grobben B, Slegers H: Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family. Biochim Biophys Acta 2003;1638:1–19.
  12. Goding JW, Terkeltaub R, Maurice M, Deterre P, Sali A, Belli SI: Ecto-phosphodiesterase/pyrophosphatase of lymphocytes and non-lymphoid cells: Structure and function of the PC-1 family. Immunol Rev 1998;161:11–26.
  13. Jin-Hua P, Goding JW, Nakamura H, Sano K: Molecular cloning and chromosomal localization of PD-Iβ (PDNP3), a new member of the human phosphodiesterase I genes. Genomics 1997;45:412–415.
  14. Andoh K, Jin-Hua P, Terashima K, Nakamura H, Sano K: Genomic structure and promoter analysis of the ecto-phosphodiesterase I gene (PDNP3) expressed in glial cells. Biochim Biophys Acta 1999;1446:213–224.
  15. Yano Y, Hayashi Y, Sano K, Shinmaru H, Kuroda Y, Yokozaki H, Yoon S, Kasuga M: Expression and localization of ecto-nucleotide pyrophosphatase/phosphodiesterase I-3 (E-NPP3/CD203c/PD-I beta/B10/gp130RB13–6) in human colon carcinoma. Int J Mol Med 2003;12:763–766.
  16. Bühring HJ, Giesert C, Kämmerer U, Sano K, Valent P: CD203c is a novel marker for basophils and glandular cells in endometrium. 15th Heidelberg Cytometry Symposium. Annual meeting of the German Society of Cytometry (DGFZ), Heidelberg, October 17–19, 2002, p 9.
  17. Bühring H-J, Simmons PJ, Pudney M, Müller R, Jarrossay D, van Agthoven A, Willheim M, Brugger W, Valent P, Kanz L: The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. Blood 1999;94:2343–2356.
  18. Bühring HJ, Seiffert M, Giesert C, Marxer A, Valent P, Kanz L, Sano K: The basophil activation marker defined by antibody 97A6 is identical with ecto-nucleotide pyrophosphatase/phosphodiesterase 3 (E-NPP3; CD203c). Blood 2001;97:3303–3305.
  19. Füreder W, Schernthaner GH, Ghannadan M, Hauswirth A, Sperr WR, Semper H, Majlesi Y, Zwirner J, Götze O, Bühring HJ, Lechner K, Valent P: Quantitative, phenotypic, and functional evaluation of basophils in myelodysplastic syndromes. Eur J Clin Invest 2001;31:894–901.
  20. Ghannadan M, Hauswirth AW, Schernthaner GH, Müller MR, Klepetko W, Schatzl G, Sperr WR, Bühring HJ, Valent P: Detection of novel CD antigens on the surface of human mast cells and basophils. Int Arch Allergy Immunol 2002;127:299–307.
  21. Platz IJ, Binder M, Marxer A, Lischka G, Valent P, Bühring HJ: Hymenoptera-venom-induced upregulation of the basophil activation marker ecto-nucleotide pyrophosphatase/phosphodiesterase 3 in sensitized individuals. Int Arch Allergy Immunol 2001;126:335–342.
  22. Binder M, Fierlbeck G, King T, Valent P, Bühring HJ: Individual hymenoptera venom compounds induce upregulation of the basophil activation marker ectonucleotide pyrophosphatase/phosphodiesterase 3 (CD203c) in sensitized patients. Int Arch Allergy Immunol 2002;129:160–168.
  23. Hauswirth AW, Natter S, Ghannadan M, Majlesi Y, Schernthaner GH, Sperr WR, Bühring HJ, Valenta R, Valent P: Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 2002;110:102–109.
  24. Boumiza R, Monneret G, Forissier MF, Savoye J, Gutowski MC, Powell WS, Bienvenu J: Marked improvement of the basophil activation test by detecting CD203c instead of CD63. Clin Exp Allergy 2003;33:259–265.
  25. Kahlert H, Cromwell O, Fiebig H: Measurement of basophil-activating capacity of grass pollen allergens, allergoids and hypoallergenic recombinant derivatives by flow cytometry using anti-CD203c. Clin Exp Allergy 2003;33:1266–1272.
  26. Hauswirth AW, Florian S, Krauth MT, Sonneck K, Sperr WR, Bühring HJ, Valent P: Interleukin-3 promotes expression of the activation-linked cell surface antigen CD03c (E-NPP3) on human blood basophils: Comparison with FcεRI-dependent cell activation, submitted.
  27. Pâris-Köhler A, Demoly P, Persi L, Lebel B, Bousquet J, Arnoux B: In vitro diagnosis of cypress pollen allergy by using cytofluorimetric analysis of basophils (Basotest). J Allergy Clin Immunol 2000;105:339–345.
  28. Gane P, Pecquet C, Lambin P, Abuaf N, Leynadier F, Rouger P: Flow cytometric evaluation of human basophils. Cytometry 1993;14:344–348.
  29. Gane P, Pequet C, Crespeau H, Lambin P, Leynadier F, Rouger P: Flow cytometric monitoring of allergen induced basophil activation. Cytometry 1995;19:361–365.
  30. Knol EF, Mul FPJ, Jansen H, Calafat J, Roos D: Monitoring human basophil activation via CD63 monoclonal antibody 435. J Allergy Clin Immunol 1991;88:328–338.
  31. Siegmund R, Vogelsang H, Machnik A, Herrmann D: Surface membrane antigen alteration on blood basophils in patients with hymenoptera venom allergy under immunotherapy. J Allergy Clin Immunol 2000;106:1190–1195.
  32. Erdmann SM, Heussen N, Moll-Slodowy S, Merk HF, Sachs B: CD63 expression on basophils as a tool for the diagnosis of pollen-associated food allergy: Sensitivity and specificity. Clin Exp Allergy 2003;33:607–614.
  33. Gamboa PM, Sanz ML, Caballero MR, Antepara I, Urrutia I, Jauregui I, Gonzalez G, Dieguez I, De Weck AL: Use of CD63 expression as a marker of in vitro basophil activation and leukotriene determination in metamizol allergic patients. Allergy 2003;58:312–317.
  34. Lambert C, Guilloux L, Dzviga C, Gourgaud-Massias C, Genin C: Flow cytometry versus histamine release analysis of in vitro basophil degranulation in allergy to Hymenoptera venom. Cytometry 2003;52B:13–19.
  35. Sanz ML, Gamboa PM, Garcia-Aviles C, Vila L, Dieguez I, Antepara I, de Weck AL: Flow-cytometric cellular allergen stimulation test in latex allergy. Int Arch Allergy Immunol 2003;130:33–39.
  36. Majlesi Y, Samorapoompichit P, Hauswirth AW, Schernthaner GH, Ghannadan M, Baghestanian M, Rezaie-Majd A, Valenta R, Sperr WR, Bühring HJ, Valent P: Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3. J Leukoc Biol 2003;73:107–117.
  37. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 1990;343:425–430.
  38. McTavish D, Sorkin EM: Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1991;42:65–89.
  39. Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 2000;101:207–213.
  40. Christians U, Jacobsen W, Floren LC: Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar? Pharmacol Ther 1998;80:1–34.
  41. Lennernäs H, Fager G: Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997;32:403–425.
  42. Marone G, Genovese A, Granata F, Forte V, Detoraki A, de Paulis A, Triggiani M: Pharmacological modulation of human mast cells and basophils. Clin Exp Allergy 2002;32:1682–1689.
  43. Massey WA, Cohan VL, MacClashan DW Jr, Gittlen SW, Kagey-Sobotka A, Lichtenstein LM, Warner JA: Protein kinase C modulates immunoglobulin E-mediated activation of human mast cells from lung and skin. I. Pharmacologic inhibition. J Pharmacol Exp Ther 1991;258:824–829.
  44. Miura K, MacGlashan DW Jr: Expression of protein kinase C isozymes in human basophils: Regulation by physiological and nonphysiological stimuli. Blood 1998;92:1206–1218.
  45. Schleimer RP, Gillespie E, Lichtenstein LM: Release of histamine from human leukocytes stimulated with the tumor-promoting phorbol diesters. I. Characterization of the response. J Immunol 1981;126:570–574.
  46. Kay AB: Allergy and Allergic Diseases. Oxford, Blackwell Science, 1997.
  47. Minkhar M, Giffard G, Lauret MG, Hassoun S, Drouet M, Sainte-Laudy J, Sabbah A: Histamino-libération (ou histamine release HR): Etude du seuil de positivité dans l’allergie aux venins d’hyménoptères. Allerg Immunol (Paris) 1996;9:313–316.
  48. Sainte-Laudy J, Sabbah A, Drouet M, Lauret MG, Loiry M: Diagnosis of venom allergy by flow cytometry. Correlation with clinical history, skin tests, specific IgE, histamine and leukotriene C4 release. Clin Exp Allergy 2000;30:1166–1171.

    External Resources

  49. Moneret-Vautrin DA, Sainte-Laudy J, Kanny G, Fremont S: Human basophil activation measured by CD63 expression and LTC4 release in IgE-mediated food allergy. Ann Allergy Asthma Immunol 1999;82:33–40.
  50. Sainte-Laudy J, Sabbah A, Vallon C, Guerin JC: Analysis of anti-IgE and allergen induced human basophil activation by flow cytometry. Comparison with histamine release. Inflamm Res 1998;47:401–408.
  51. Sainte-Laudy J, Vallon C, Guerin JC: Diagnosis of latex allergy: Comparison of histamine release and flow cytometric analysis of basophil activation. Inflamm Res 1996;45:S35–S36.
  52. Gamboa PM, Sanz ML, Urrutia I, Jauregui I, Antepara I, Dieguez I, De Weck AL: CD63 expression by flow cytometry in the in vitro diagnosis of allergy to omeprazole. Allergy 2003;58:538–539.
  53. Sanz ML, Gamboa PM, Antepara I, Uasuf C, Vila L, Garcia-Aviles C, Chazot M, De Weck AL: Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics. Clin Exp Allergy 2002;32:277–286.
  54. Sanz ML, Sanchez G, Gamboa PM, Vila L, Uasuf C, Chazot M, Dieguez I, De Weck AL: Allergen-induced basophil activation: CD63 cell expression detected by flow cytometry in patients allergic to Dermatophagoides pteronyssinus and Lolium perenne. Clin Exp Allergy 2001;31:1007–1013.
  55. Wedi B, Novacovic V, Koerner M, Kapp A: Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression-inhibitory effects of anti-inflammatory drugs. J Allergy Clin Immunol 2000;105:552–560.
  56. Crockard AD, Ennis M: Laboratory-based allergy diagnosis: Should we go with the flow? Clin Exp Allergy 2001;31:975–977.
  57. Valent P, Bettelheim P: The human basophil. Crit Rev Oncol Hematol 1990;10:327–352.
  58. Kepley CL, Youssef L, Andrews RP, Wilson BS, Oliver JM: Syk deficiency in nonreleaser basophils. J Allergy Clin Immunol 1999;104:279–284.
  59. Hiller R, Laffer S, Harwanegg C, Huber M, Schmidt WM, Twardosz A, Barletta B, Becker WM, Blaser K, Breiteneder H, Chapman M, Crameri R, Duchene M, Ferreira F, Fiebig H, Hoffmann-Sommergruber K, King TP, Kleber-Janke T, Kurup VP, Lehrer SB, Lidholm J, Muller U, Pini C, Reese G, Scheiner O, Scheynius A, Shen HD, Spitzauer S, Suck R, Swoboda I, Thomas W, Tinghino R, Van Hage-Hamsten M, Virtanen T, Kraft D, Muller MW, Valenta R: Microarrayed allergen molecules: Diagnostic gatekeepers for allergy treatment. FASEB J 2002;16:414–416.
  60. King TP, Spangford MD: Structure and biology of stinging insect venom allergens. Int Arch Allergy Immunol 2000;123:99–106.
  61. King TP, Jim SY, Monsalve RI, Kagey-Sobotka A, Lichtenstein LM, Spangfort MD: Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: Hybrids of yellow jacket and paper wasp venom allergen antigen 5s. J Immunol 2001;166:6057–6065.
  62. King TP, Lu G, Gonzalez M, Qian N, Soldatova L: Yellow jacket venom allergens, hyaluronidase and phospholipase: Sequence similarity and antigenic cross-reactivity with their hornet and wasp homologs and possible implications for clinical allergy. J Allergy Clin Immunol 1996;98:588–600.
  63. Breiteneder H, Pettenburger K, Bito A, Valenta R, Kraft D, Rumpold H, Scheiner O, Breitenbach M: The gene coding for the major birch pollen allergen Betv1, is highly homologous to a pea disease resistance response gene. EMBO J 1989;8:1935–1938.
  64. Susani M, Jertschin P, Dolecek C, Sperr WR, Valent P, Ebner C, Kraft D, Valenta R, Scheiner O: High level expression of birch pollen profilin (Bet v 2) in Escherichia coli: Purification and characterization of the recombinant allergen. Biochem Biophys Res Commun 1995;215:250–263.
  65. Valenta R, Vrtala S, Laffer S, Spitzauer S, Kraft D: Recombinant allergens. Allergy 1998;53:552–561.
  66. Vrtala S, Susani M, Sperr WR, Valent P, Laffer S, Dolecek C, Kraft D, Valenta R: Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5). J Allergy Clin Immunol 1996;97:781–787.
  67. Dudler T, Chen WQ, Wang S, Schneider T, Annand RR, Dempcy RO, Crameri R, Gmachl M, Suter M, Gelb MH: High-level expression in Escherichia coli and rapid purification of enzymatically active honey bee venom phospholipase A2. Biochim Biophys Acta 1992;1165:201–210.
  68. Scott DL, Otwinowski Z, Gelb MH, Sigler PB: Crystal structure of bee-venom phospholipase A2 in a complex with a transition-state analogue. Science 1990;250:1563–1566.
  69. King TP, Sobotka AK, Kochoumian L, Lichtenstein LM: Allergens of honey bee venom. Arch Biochem Biophys 1976;172:661–671.
  70. King TP, Alagon AC, Kuan J, Sobotka AK, Lichtenstein LM: Immunochemical studies of yellowjacket venom proteins. Mol Immunol 1983;20:297–308.
  71. Monsalve RI, Lu G, King TP: Expressions of recombinant venom allergen, antigen 5 of yellowjacket (Vespula vulgaris) and paper wasp (Polistes annularis), in bacteria or yeast. Protein Expr Purif 1999;16:410–416.
  72. Hartl A, Hochreiter R, Stepanoska T, Ferreira F, Thalhamer J: Characterization of the protective and therapeutic efficiency of a DNA vaccine encoding the major birch pollen allergen Bet v 1a. Allergy 2004;59:65–73.
  73. Reininger R, Swoboda I, Bohle B, Hauswirth A, Valent P, Rumpold H, Valenta R, Spitzauer S: Characterization of recombinant cat albumin. Clin Exp Allergy 2003;33:1695–1702.
  74. Koppelman SJ, Knol EF, Vlooswijk RA, Wensing M, Knulst AC, Hefle SL, Gruppen H, Piersma S: Peanut allergen Ara h 3: Isolation from peanuts and biochemical characterization. Allergy 2003;58:1144–1151.
  75. Priyadarsiny P, Swain PK, Sarma PU: Expression and characterization of Asp fI, an immunodominant allergen/antigen of A. fumigatus in insect cell. Mol Cell Biochem 2003;252:157–163.
  76. Wang F, Robotham JM, Teuber SS, Sathe SK, Roux KH: Ana o 2, a major cashew (Anacardium occidentale L.) nut allergen of the legumin family. Int Arch Allergy Immunol 2003;132:27–39.
  77. Lehmann K, Hoffmann S, Neudecker P, Suhr M, Becker WM, Rosch P: High-yield expression in Escherichia coli, purification, and characterization of properly folded major peanut allergen Ara h 2. Protein Expr Purif 2003;31:250–259.
  78. Jeong KY, Lee J, Lee IY, Ree HI, Hong CS, Yong TS: Allergenicity of recombinant Bla g 7, German cockroach tropomyosin. Allergy 2003;58:1059–1063.
  79. Shen HD, Chou H, Tam MF, Chang CY, Lai HY, Wang SR: Molecular and immunological characterization of Pen ch 18, the vacuolar serine protease major allergen of Penicillium chrysogenum. Allergy 2003;58:993–1002.
  80. Roux KH, Teuber SS, Sathe SK: Tree nut allergens. Int Arch Allergy Immunol 2003;131:234–244.
  81. Valenta R, Kraft D: From allergen structure to new forms of allergen-specific immunotherapy. Curr Opin Immunol 2002;14:718–727.
  82. Valenta R, Duchène M, Pettenburger K, Sillaber C, Valent P, Bettelheim P, Breitenbach M, Rumpold H, Kraft D, Scheiner O: Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science 1991;253:557–560.
  83. Valenta R, Duchène M, Ebner C, Valent P, Sillaber C, Deviller P, Ferreira F, Tejkl M, Edelmann H, Kraft D, Schreiner O: Profilins constitute a novel family of functional plant pan-allergens. J Exp Med 1992;175:377–385.
  84. Valenta R, Sperr WR, Ferreira F, Valent P, Sillaber C, Tejkl M, Duchène M, Ebner C, Lechner K, Kraft D, Scheiner O: Induction of specific histamine release from basophils with purified natural and recombinant birch pollen allergens. J Allergy Clin Immunol 1993;91:88–97.
  85. Niederberger V, Pauli G, Grönlund H, Fröschl R, Rumpold H, Kraft D, Valenta R, Spitzauer S: Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: A quantitative IgE inhibition study with sera from different populations. J Allergy Clin Immunol 1998;102:579–591.
  86. Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Grönlund H: The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 1999;29:896–904.
  87. Singh MB, de Weerd N, Bhalla PL: Genetically engineered plant allergens with reduced anaphylactic activity. Int Arch Allergy Immunol 1999;119:75–85.
  88. Ferreira F, Wallner M, Breiteneder H, Hartl A, Thalhamer J, Ebner C: Genetic engineering of allergens: Future therapeutic products. Int Arch Allergy Immunol 2002;128:171–178.
  89. Rossi RE, Monasterolo G, Monasterolo S: Measurement of IgE antibodies against purified grass-pollen allergens (Phl p 1, 2, 3, 4, 5, 6, 7, 11, and 12) in sera of patients allergic to grass pollen. Allergy 2001;56:1180–1185.
  90. Wagner S, Breiteneder H, Simon-Nobbe B, Susani M, Krebitz M, Niggemann B, Brehler R, Scheiner O, Hoffmann-Sommergruber K: Hev b 9, an enolase and a new cross-reactive allergen from hevea latex and molds. Purification, characterization, cloning and expression. Eur J Biochem 2000;267:7006–7014.
  91. Binder M, Mahler V, Hayek B, Sperr WR, Schöller M, Prozell S, Wiedermann G, Valent P, Valenta R, Duchène M: Molecular and immunological characterization of arginine kinase from the Indianmeal moth, Plodia interpunctella, a novel cross-reactive invertebrate pan-allergen. J Immunol 2001;167:5470–5477.
  92. Wagner B, Buck D, Hafner C, Sowka S, Niggemann B, Scheiner O, Breiteneder H: Hev b 7 is a Hevea brasiliensis protein associated with latex allergy in children with spina bifida. J Allergy Clin Immunol 2001;108:621–627.
  93. Scheurer S, Pastorello EA, Wangorsch A, Kastner M, Haustein D, Vieths S: Recombinant allergens Pru av 1 and Pru av 4 and a newly identified lipid transfer protein in the in vitro diagnosis of cherry allergy. J Allergy Clin Immunol 2001;107:724–731.
  94. Swoboda I, Bugajska-Schretter A, Verdino P, Keller W, Sperr WR, Valent P, Valenta R, Spitzauer S: Recombinant carp parvalbumin, the major cross-reactive fish allergen: A tool for diagnosis and therapy of fish allergy. J Immunol 2002;168:4576–4584.
  95. Fluckiger S, Fijten H, Whitley P, Blaser K, Crameri R: Cyclophilins, a new family of cross-reactive allergens. Eur J Immunol 2002;32:10–17.
  96. Valenta R: The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002;2:446–453.
  97. King TP, Jim SY, Rathke G, Bühring HJ: Allergenicity and immunogenicity of hybrids of yellow jacket and paper wasp venom allergen antigen 5s (Ves v 5 and Pol a 5), submitted.
  98. Neudecker P, Lehmann K, Nerkamp J, Haase T, Wangorsch A, Fötisch K, Hoffmann S, Rösch P, Vieths S, Scheurer S: Mutational epitope analysis of Pru av 1 and Api g 1, the major allergens of cherry (Prunus avium) and celery (Apium graveolens): Correlating IgE reactivity with three-dimensional structure. Biochem J 2003;376:97–107.
  99. Swoboda I, De Weerd N, Bhalla PL, Niederberger V, Sperr WR, Valent P, Kahlert H, Fiebig H, Verdino P, Keller W, Ebner C, Spitzauer S, Valenta R, Singh MB: Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: Candidates for grass pollen-specific immunotherapy. Eur J Immunol 2002;32:270–280.
  100. Valenta R, Vrtala S, Focke-Tejkl M, Twardosz A, Swoboda I, Bugajska-Schretter A, Spitzauer S, Kraft D: Synthetic and genetically engineered allergen derivatives for specific immunotherapy of type I allergy. Clin Allergy Immunol 2002;16:495–517.
  101. Vrtala S, Hirtenlehner K, Susani M, Akdis M, Kussebi F, Akdis CA, Blaser K, Hufnagl P, Binder BR, Politou A, Pastore A, Vangelista L, Sperr WR, Semper H, Valent P, Ebner C, Kraft D, Valenta R: Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 2001;15:2045–2047.
  102. Vrtala S, Akdis CA, Budak F, Akdis M, Blaser K, Kraft D, Valenta R: T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J Immunol 2000;165:6653–6659.
  103. Müller U: Recent developments and future strategies for immunotherapy of insect venom allergy. Curr Opin Allergy Clin Immunol 2003;3:299–303.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50